Table 9Randomized controlled trials assessing risk of fracture for risedronate, relative to different doses of risedronate, by fracture group (not included in prior systematic reviews)

Author, YearStudy DurationType of FractureNumber of Fractures, Risedronate, Weekly*Number of Fractures, Risedronate, DailyOdds Ratio (95% CI)
Risedronate 2.5 Mg/D vs. Risedronate 17.5 mg/Week
Vertebral
Original 2007 report
Kishimoto, 20069948 weeksVertebral6/2225/2271.23 (0.37, 4.00)
Update report: No new studies
Risedronate 5 Mg/D vs. Risedronate 35 mg/Week
Vertebral
Original 2007 report
Brown, 200210024 monthsNew morphometric vertebral6/4805/4851.21 (0.37, 3.98)
Harris, 200410124 monthsMorphometric vertebral12/4157/4221.92 (0.75, 4.88)
Update report: No new studies
Nonvertebral
Original 2007 report
Brown, 200210024 monthsAny non-vertebral24/48028/4850.86 (0.49, 1.50)
Update report: No new studies
Risedronate 5 Mg/D vs. Risedronate 50 mg/Week
Vertebral
Original 2007 report
Brown, 200210024 monthsNew morphometric vertebral6/4802/4912.8 (0.7, 11.26)
Harris, 200410124 monthsMorphometric vertebral12/4157/4221.74 (0.70, 4.32)
Update report: No new studies
Nonvertebral
Original 2007 report
Brown, 200210024 monthsAny non-vertebral24/48024/4911.02 (0.57, 1.83)
Update report: No new studies
Risedronate 35 Mg/Week vs. Risedronate 50 mg/Week
Vertebral
Original 2007 report
Brown, 200210024 monthsNew morphometric vertebral5/4852/4911.19 (0.68, 2.08)
Harris, 200410124 monthsMorphometric vertebral12/4157/4220.9 (0.30, 2.68)
Update report: No new studies
Non-Vertebral
Original 2007 report
Brown, 200210024 monthsAny nonvertebral28/48524/4911.19 (0.68, 2.08)
Update report: No new studies
Risedronate 150 mg Daily for 2 Consecutive Days per Month vs. Risedronate 5 mg/D
Vertebral
Original 2007 report: No comparable studies from the original report
Update report
Delmas, 20088512 monthsVertebral6/6167/6130.85 (0.29, 2.54)
Delmas, 20088612 monthsVertebral8/6508/6420.99 (0.37, 2.65)

NC=not calculable

*

Number of fractures/number of participants included in treatment arm.

An odds ratio greater than 1 indicates higher risk of fracture in the group receiving active treatment.

From: Results

Cover of Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: Update of a 2007 Report
Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: Update of a 2007 Report [Internet].
Comparative Effectiveness Reviews, No. 53.
Crandall CJ, Newberry SJ, Diamant A, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.